Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 13 of 13 matching drugs for LIMK2 — including drugs targeting any of its 20 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
eras-007, encorafenib, cetuximab, palbociclib LIMK2 Direct 1
pazopanib SH2B3 SSL via SH2B3 2
biopsy, biospecimen collection, ceralasertib, computed tomography, echocardiography, multigated acquisition scan, positron emission tomography, trastuzumab deruxtecan ATR SSL via ATR 1
ceralasertib, olaparib, durvalumab ATR SSL via ATR 1
cisplatin, carboplatin, etoposide, durvalumab, ceralasertib ATR SSL via ATR 1
pazopanib, 5-fu, oxaliplatin, leukovorin (flo) SH2B3 SSL via SH2B3 1
pazopanib, lapatinib SH2B3 SSL via SH2B3 1
pazopanib, placebo SH2B3 SSL via SH2B3 1
pegilodecakin, paclitaxel or docetaxel and carboplatin or cisplatin, folfox (oxaliplatin/leucovorin/5-fluorouracil), gemcitabine/nab-paclitaxel, capecitabine, pazopanib, pembrolizumab, paclitaxel, nivolumab, gemcitabine/carboplatin SH2B3 SSL via SH2B3 1
topotecan, pazopanib SH2B3 SSL via SH2B3 1
clofarabine POLD1 SSL via POLD1 yes 0
gemcitabine POLD1 SSL via POLD1 yes 0
gemcitabine hydrochloride POLD1 SSL via POLD1 yes 0
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.